Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05675449
- Locations
- 🇺🇸
Clinical Research Advisors (Encino Satellite Location), Encino, California, United States
🇺🇸Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California, United States
🇺🇸Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California, United States
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇺🇸
Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
🇦🇺Investigational Site Number : 0360001, Saint Leonards, New South Wales, Australia
Home Treatment with Carfilzomib in Patients with Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Thomas Lund
- Target Recruit Count
- 12
- Registration Number
- NCT05620238
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇧🇪CHR de la Citadelle, Liege, Belgium
🇧🇷Hospitais Integradaos da Gavea S/A - DF Star, Brasilia, Brazil
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05552976
- Locations
- 🇨🇳
Local Institution - 0058, Kunming, Yunnan, China
🇩🇪Universitaetsklinikum Heidelberg, Heidelberg, Germany
🇺🇸USA Mitchell Cancer Institute, Mobile, Alabama, United States
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT05509374
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- Conditions
- ISS Stage III Plasma Cell MyelomaMultiple Myeloma
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Multigated Acquisition ScanProcedure: Biospecimen CollectionProcedure: EchocardiographyProcedure: Chest Radiography
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 75
- Registration Number
- NCT05497804
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in RelapseMultiple Myeloma, Refractory
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05495620
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.